Fig. 2: Suggested cardiac monitoring prior to and during Multiple myeloma treatment. | Blood Cancer Journal

Fig. 2: Suggested cardiac monitoring prior to and during Multiple myeloma treatment.

From: Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies

Fig. 2: Suggested cardiac monitoring prior to and during Multiple myeloma treatment.The alternative text for this image may have been generated using AI.

MM multiple myeloma, CV cardiovascular, HTN hypertension, DM diabetes mellitus, CHF congestive heart failure, CAD coronary artery disease, HD heart disease, CGA comprehensive geriatric assessment, ECG electrocardiogram, TTE transthoracic echocardiogram, NT-proBNP N-terminal pro-B-type natriuretic peptide, EF ejection fraction, CAR-T chimeric antigen receptor T-cell therapy.

Back to article page